Teslexivir
- Generic Name
- Teslexivir
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
Phase 1
Completed
- Conditions
- Anogenital WartsCondylomata AcuminataHuman Papillomavirus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Anaconda Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01532102
- Locations
- 🇦🇷
Hospotal Italinao de Buenos Aires - Dept of Dermatology and Gynecology, Buenos Aires, Argentina
🇫🇷SGS Aster, Paris, France
🇫🇷Hopital Henri Mondor-Dept of Dermatology, Creteil, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath